Clinical trials

  • BELIMUMAB for Antibody-mediated rejection (kidney transplant)|High HLA sensitization (transplant candidates)
  • PEMBROLIZUMAB for Low-grade serous ovarian cancer | Fallopian tube cancer | Primary peritoneal cancer | Recurrent platinum-sensitive ovarian cancer
  • CAPMATINIB for Unresectable metastatic non-small cell lung cancer
  • PELACARSEN for Cardiovascular disease | Arteriosclerotic cardiovascular disease
  • NIPOCALIMAB for Chronic inflammatory demyelinating polyneuropathy
  • Sigvotatug Vedotin for Esophageal cancer|Pancreatic cancer|Skin cancer|Gastric cancer|Head and neck cancer|Ovarian cancer|Non-small cell lung cancer|Cervical cancer|Breast cancer|Bladder cancer
  • Dapagliflozin for Alport syndrome
  • phospholipid fraction, bovine lung for Idiopathic pulmonary fibrosis
  • Girentuximab (labelled with Zirconium-89) for Gastroenteropancreatic neuroendocrine neoplasms|Hepatocellular carcinoma|Biliary tract cancer
  • BIM2b for Glioblastoma
  • Durvalumab for Resectable non-small cell lung cancer (stage IIB–IIIB, N2)
  • REPOTRECTINIB for Stage III/IV non-small cell lung cancer (ROS1-rearranged)